Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions

Checkpoint inhibitor (CPI) therapy with anti–PD-1 antibodies has been associated with mixed outcomes in small cohorts of patients with relapsed aggressive B-cell lymphomas after CAR-T failure. To define CPI therapy efficacy more definitively in this population, we retrospectively evaluated clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Major, Ajay, Yu, Jovian, Shukla, Navika, Che, Yan, Karrison, Theodore G., Treitman, Rachel, Kamdar, Manali K., Haverkos, Bradley M., Godfrey, James, Babcook, Melissa A., Voorhees, Timothy J., Carlson, Sophie, Gaut, Daria, Oliai, Caspian, Romancik, Jason T., Winter, Allison M., Hill, Brian T., Bansal, Radhika, Villasboas Bisneto, Jose C., Nizamuddin, Imran A., Karmali, Reem, Fitzgerald, Lindsey A., Stephens, Deborah M., Pophali, Priyanka A., Trabolsi, Asaad, Schatz, Jonathan H., Hu, Marie, Bachanova, Veronika, Slade, Michael J., Singh, Nathan, Ahmed, Nausheen, McGuirk, Joseph P., Bishop, Michael R., Riedell, Peter A., Kline, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425681/
https://www.ncbi.nlm.nih.gov/pubmed/37026796
http://dx.doi.org/10.1182/bloodadvances.2023010016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425681/
https://www.ncbi.nlm.nih.gov/pubmed/37026796
http://dx.doi.org/10.1182/bloodadvances.2023010016

Ejemplares similares